# APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)

> **NCT04638309** · PHASE1 · TERMINATED · sponsor: **Aprea Therapeutics** · enrollment: 4 (actual)

## Conditions studied

- MDS
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** APR-548 + Azacitidine

## Key facts

- **NCT ID:** NCT04638309
- **Lead sponsor:** Aprea Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-20
- **Primary completion:** 2022-04-25
- **Final completion:** 2022-04-25
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04638309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04638309, "APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04638309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*